Molecular Mechanisms Contributing to Glucocorticoid Resistance in Lymphoid Malignancies

Overview

Journal Cancer Drug Resist

Date 2022 May 18

PMID 35582582

Authors

Blanca Scheijen

Affiliations

Soon will be listed here.

Abstract

Despite the introduction of many novel therapies into the clinic to target hematological malignancies, glucocorticoids (GCs) still remain one of the cornerstone drugs in first-line treatment of lymphoid tumors. However, a significant portion of the patients display acquired GC therapy resistance. This review will describe the different molecular mechanisms that contribute to GC resistance in lymphoid tumors. These include suppression of glucocorticoid receptor (GR) expression, activation of cell signaling pathways that modulate GR function, differential recruitment of transcriptional co-regulators, and changes in chromatin accessibility. Many of these mechanisms are interconnected to genetic alterations associated with relapsed disease in lymphoid malignancies.

Citing Articles

IKZF1 and BTG1 silencing reduces glucocorticoid response in B-cell precursor acute leukemia cell line.

de Albuquerque A, Lopes B, Fernandes R, Gimba E, Emerenciano M Hematol Transfus Cell Ther. 2024; 46 Suppl 6:S163-S170.

PMID: 39095315 PMC: 11726076. DOI: 10.1016/j.htct.2024.05.004.

Plausible mechanism of drug resistance and side-effects of COVID-19 therapeutics: a bottleneck for its eradication.

Das S, Nath S, Shahjahan , Dey S Daru. 2024; 32(2):801-823.

PMID: 39026019 PMC: 11554973. DOI: 10.1007/s40199-024-00524-z.

Exploring the nexus of nuclear receptors in hematological malignancies.

Manickasamy M, Sajeev A, BharathwajChetty B, AlQahtani M, Abbas M, Hegde M Cell Mol Life Sci. 2024; 81(1):78.

PMID: 38334807 PMC: 10858172. DOI: 10.1007/s00018-023-05085-z.

JUN mediates glucocorticoid resistance by stabilizing HIF1a in T cell acute lymphoblastic leukemia.

Zhang Z, Shi J, Wu Q, Zhang Z, Liu X, Ren A iScience. 2023; 26(11):108242.

PMID: 38026210 PMC: 10661119. DOI: 10.1016/j.isci.2023.108242.

Screening of Anti-Inflammatory Activity and Metabolomics Analysis of Endophytic Fungal Extracts; Identification and Characterization of Perylenequinones and Terpenoids from the Interesting Active Alternaria Endophyte.

Spina R, Ropars A, Bouazzi S, Dadi S, Lemiere P, Dupire F Molecules. 2023; 28(18).

PMID: 37764307 PMC: 10534442. DOI: 10.3390/molecules28186531.

References

Eichenauer D, Andre M, Johnson P, Fossa A, Casasnovas O, Engert A . Controversies in the Treatment of Classical Hodgkin Lymphoma. Hemasphere. 2019; 2(5):e149. PMC: 6407792. DOI: 10.1097/HS9.0000000000000149. View

Sapolsky R, Romero L, Munck A . How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev. 2000; 21(1):55-89. DOI: 10.1210/edrv.21.1.0389. View

Lu N, Cidlowski J . Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes. Mol Cell. 2005; 18(3):331-42. DOI: 10.1016/j.molcel.2005.03.025. View

Lonard D, OMalley B . Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol Cell. 2007; 27(5):691-700. DOI: 10.1016/j.molcel.2007.08.012. View

Perissi V, Aggarwal A, Glass C, Rose D, Rosenfeld M . A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell. 2004; 116(4):511-26. DOI: 10.1016/s0092-8674(04)00133-3. View

Bassan R, Bourquin J, DeAngelo D, Chiaretti S . New Approaches to the Management of Adult Acute Lymphoblastic Leukemia. J Clin Oncol. 2018; :JCO2017773648. DOI: 10.1200/JCO.2017.77.3648. View

Robak P, Drozdz I, Szemraj J, Robak T . Drug resistance in multiple myeloma. Cancer Treat Rev. 2018; 70:199-208. DOI: 10.1016/j.ctrv.2018.09.001. View

Agarwal S, Mirzoeva S, Readhead B, Dudley J, Budunova I . PI3K inhibitors protect against glucocorticoid-induced skin atrophy. EBioMedicine. 2019; 41:526-537. PMC: 6441871. DOI: 10.1016/j.ebiom.2019.01.055. View

Paakinaho V, Kaikkonen S, Makkonen H, Benes V, Palvimo J . SUMOylation regulates the chromatin occupancy and anti-proliferative gene programs of glucocorticoid receptor. Nucleic Acids Res. 2013; 42(3):1575-92. PMC: 3919585. DOI: 10.1093/nar/gkt1033. View

10.

Jones C, Gearheart C, Fosmire S, Delgado-Martin C, Evensen N, Bride K . MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. Blood. 2015; 126(19):2202-12. PMC: 4635116. DOI: 10.1182/blood-2015-04-639138. View

11.

Bonapace L, Bornhauser B, Schmitz M, Cario G, Ziegler U, Niggli F . Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest. 2010; 120(4):1310-23. PMC: 2846044. DOI: 10.1172/JCI39987. View

12.

Paugh S, Bonten E, Savic D, Ramsey L, Thierfelder W, Gurung P . NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nat Genet. 2015; 47(6):607-14. PMC: 4449308. DOI: 10.1038/ng.3283. View

13.

Chauhan D, Anderson K . Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications. Apoptosis. 2003; 8(4):337-43. DOI: 10.1023/a:1024164700094. View

14.

van Galen J, Kuiper R, van Emst L, Levers M, Tijchon E, Scheijen B . BTG1 regulates glucocorticoid receptor autoinduction in acute lymphoblastic leukemia. Blood. 2010; 115(23):4810-9. DOI: 10.1182/blood-2009-05-223081. View

15.

John S, Sabo P, Thurman R, Sung M, Biddie S, Johnson T . Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. Nat Genet. 2011; 43(3):264-8. PMC: 6386452. DOI: 10.1038/ng.759. View

16.

Galliher-Beckley A, Williams J, Collins J, Cidlowski J . Glycogen synthase kinase 3beta-mediated serine phosphorylation of the human glucocorticoid receptor redirects gene expression profiles. Mol Cell Biol. 2008; 28(24):7309-22. PMC: 2593428. DOI: 10.1128/MCB.00808-08. View

17.

Vernocchi S, Battello N, Schmitz S, Revets D, Billing A, Turner J . Membrane glucocorticoid receptor activation induces proteomic changes aligning with classical glucocorticoid effects. Mol Cell Proteomics. 2013; 12(7):1764-79. PMC: 3708164. DOI: 10.1074/mcp.M112.022947. View

18.

Gutierrez-Mecinas M, Trollope A, Collins A, Morfett H, Hesketh S, Kersante F . Long-lasting behavioral responses to stress involve a direct interaction of glucocorticoid receptors with ERK1/2-MSK1-Elk-1 signaling. Proc Natl Acad Sci U S A. 2011; 108(33):13806-11. PMC: 3158237. DOI: 10.1073/pnas.1104383108. View

19.

Castro J, Sandoval-Sus J, Bole J, Rassenti L, Kipps T . Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia. 2008; 22(11):2048-53. PMC: 5289283. DOI: 10.1038/leu.2008.214. View

20.

Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam R . Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell. 2006; 10(4):331-42. DOI: 10.1016/j.ccr.2006.09.006. View